Analyst Ratings for G1 Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have published their opinion on G1 Therapeutics (NASDAQ:GTHX) stock, with three giving bullish ratings and one somewhat bullish. The average 12-month price target for G1 Therapeutics is $12.25, representing a 31.94% decrease from the previous average price target of $18.00.
October 06, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have given mostly bullish ratings to G1 Therapeutics, but the average 12-month price target has decreased significantly.
While the majority of analysts have given bullish ratings to G1 Therapeutics, the significant decrease in the average 12-month price target could negatively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100